Valneva (VLA) Q4 2025 earnings summary

Executive summary

• Total revenues for 2025 reached €174.7 million, up from 2024, with product sales of €157.9 million and a year-end cash position of €109.7 million, supported by successful debt refinancing and a 21% reduction in operating cash burn.

• Proprietary product sales grew 9% year-over-year at constant exchange rates, with IXIARO/JESPECT sales up 4.6% to €98.4 million and IXCHIQ sales more than doubling to €8.4 million.

• Strategic focus remains on growing the commercial business, maximizing R&D value, and leveraging an integrated business model across commercial, manufacturing, and development.

• Key pipeline programs advanced, with all vaccinations completed in the pivotal Phase 3 Lyme disease study and data expected in H1 2026.

• Disciplined cash management and enhanced financial flexibility through debt refinancing and cost control initiatives.

Financial highlights

• Product sales declined 3.3% year-over-year, mainly due to a planned 42.3% reduction in third-party sales and FX impact; proprietary product sales grew 9% at constant exchange rates.

• IXIARO/JESPECT sales rose 4.6% to €98.4 million; DUKORAL sales were €31.9 million, slightly down due to currency effects and distribution transition in Germany.

• IXCHIQ sales surged 127.8% to €8.4 million, supported by launches in Europe, Brazil, and outbreak response.

• Adjusted EBITDA loss was €59.4 million; net loss for the period was €115.2 million, mainly due to the absence of a €90.8 million one-time gain from the prior year’s PRV sale.

• Gross margin on commercial product sales (excluding IXCHIQ): 50.8%; IXIARO margin was 59.6%, DUKORAL 33.3%, and IXCHIQ negative due to inventory write-offs.

Outlook and guidance

• 2026 revenue guidance is €155–170 million, with product sales expected between €145–160 million, reflecting continued growth in core brands and further wind-down of third-party sales.

• Operating cash burn is expected to decline further in 2026, with continued investment in R&D and proprietary product growth.

• Financial self-sustainability and potential profitability targeted from 2027, contingent on successful Lyme vaccine approval and commercialization.